Nektar Therapeutics (NKTR) is implementing a cost restructuring plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Broadcom rises 3% on OpenAI custom "Jalapeño" chip reveal
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate Outlook
April 25, 2022 4:30 PM EDTCompany focusing on key pipeline programs NKTR-358, NKTR-255 and core research programs
Cost restructuring plan results in cash runway into the first half of 2025
Analyst and investor conference call today at 5:00 PM ET (2:00 PM PT)
SAN FRANCISCO, April 25, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced a new strategic plan focused on prioritizing key research and development efforts that will be most impactful to the company's... More
